Founder and Managing Director, BioMed Ventures
Bruce is the founder and Managing Director of BioMed Ventures, the life science investment arm of BioMed Realty. He maintains extensive relationships with world-class institutional investors, entrepreneurs, and executives developed over eighteen years of investing and operating in the biotech sector. Bruce is a co-founder of Equillium – a new biotech company advancing a validated, novel antibody therapeutic into multiple clinical indications for grave autoimmune and inflammatory diseases. Previously he was co-founder and CEO of Rincon Pharmaceuticals from 2004 until its acquisition in 2008, Chief Business Officer at Anaphore, and Head of Corporate Development at Ambit Biosciences. Bruce led investments and served in a board capacity at over twenty-five life science companies, including Aegea, Amplyx, Anaptys, Auspex, Breathe, CardioFocus, Compass, Edge, Genalyte, Histogenics, NanoString, NeuroVia, OptiScan, Promedior, Receptos, Tracon, and Zosano. Bruce received his Bachelor of Arts degree from Dartmouth College and Masters of Business Administration degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.